GLP-1 therapies have transformed metabolic medicine, but long-term outcomes depend on the biology behind the signal. This session reframes GLP-1 as a host–microbiome signalling pathway, highlighting how microbial metabolites, gut barrier function, and low-grade inflammation influence metabolic regulation - and how gut-related genetics shape each of these processes. Understanding these genetic insights provides a new dimension for designing sustainable, long-term metabolic strategies.
The GLP-1 Era
Gut genetics & microbiome in metabolic signalling
Participants will explore how functional stool testing and host-genetic analysis reveal the drivers of metabolic dysregulation, enabling personalized interventions that restore physiological balance, optimize satiety, and enhance metabolic resilience.
Functional Medicine Consultant
Diana Siepmann is a certified Functional Medicine Consultant with more than eight years of experience translating complex biology into clinically actionable insights. With an educational background and professional experience spanning hormone, gut, and immune health, she has more recently applied this comprehensive knowledge to providing personalized support in (peri)menopause.
A key aspect of this work is the optimization of metabolic health, which has led to a particular interest in how gut function, microbial ecology, and genetic variation interact to influence metabolic regulation-mechanisms that are highly relevant in this life stage but broadly applicable across patient populations.
Through her analytical and educational approach, she supports physicians and other healthcare professionals by integrating functional testing and DNA-based insights to translate complex systems biology into practical, personalized strategies aimed at restoring long-term physiological resilience.